August 21, 2026
Research
Why Resveratrol Needs BioPerine: The Absorption Problem
September 5, 2026 · 7 min read
Swallow 5 g of resveratrol and peak blood levels of resveratrol reach 539 ng/mL. Its sulfate metabolite reaches 4,294 ng/mL. That gap is the reason nearly every resveratrol capsule on the shelf now lists black pepper extract underneath the headline ingredient.
BioPerine is a branded piperine extract, standardised to about 95% piperine. The pitch is compact and appealing. Piperine slows the enzymes that dismantle resveratrol, so more of the parent molecule survives.
The mechanism is real. The human evidence behind it is thinner than the label suggests, and worth knowing before you pay for it.
Nearly all of it gets in. Almost none of it stays
Six adults swallowed 25 mg of radiolabelled resveratrol in a 2004 study at the Medical University of South Carolina. At least 70% of the dose was absorbed. Unchanged resveratrol in plasma never rose above 5 ng/mL.
Absorption was never the problem. Survival is.
A dose-ladder study makes the same point at much larger doses. Forty healthy adults took a single dose of 0.5, 1, 2.5 or 5 g. At the top dose, resveratrol itself made up about 1,319 ng·h/mL of the 24-hour exposure. Its three main conjugates made up roughly 49,000.
Put plainly: you can take the resveratrol in several hundred bottles of red wine and still sit below the level most lab work uses in a dish.
The enzyme that eats it
Two reactions do nearly all the damage. Glucuronidation bolts a sugar acid onto the molecule. Sulfation bolts on a sulfate group. Both make it easy to dissolve in water, and easy for the kidneys to flush.
Resveratrol has three hydroxyl groups, so it offers three convenient handles. The gut wall starts the job as the dose crosses. The liver finishes it on the first pass. The 2004 tracer study found that fast sulfate tagging is the step that sets the pace.
That leaves three ways to change the outcome. Take more. Dissolve it faster. Or slow the conjugating enzymes down. Piperine aims squarely at the third.
What piperine is meant to do
Piperine does block enzymes, and that part has been measured properly. In sheets of human gut cells it blocked the pump that shuttles digoxin back out, with an IC50 of 15.5 µmol/L. In human liver microsomes — the enzyme-rich fraction of liver cells — it slowed CYP3A4 at 36 to 77 µmol/L.
Key Study: Piperine Inhibits Two Major Clearance Routes
Piperine blocked P-glycoprotein-mediated digoxin transport in human intestinal cells (IC50 15.5 µmol/L) and inhibited CYP3A4 in human liver microsomes (Ki 36-77 µmol/L). Both systems sit in the gut wall and liver, where most first-pass clearance happens.
Source: Bhardwaj et al., Journal of Pharmacology and Experimental Therapeutics, 2002 (cell and microsome study, not human dosing).
Two caveats sit on top of that. These were levels in a dish, and a 10 mg capsule hits the gut lining far harder than it hits the liver. The same trait that makes piperine useful also makes it a drug-interaction question rather than a free lunch.
If you take prescribed medication, that is a conversation for your pharmacist, not a footnote.
The mouse study behind the label
The number the industry quotes comes from one 2011 experiment. C57BL mice received resveratrol at 100 mg/kg by gavage, with or without piperine at 10 mg/kg.
Key Study: 229% Exposure — in Mice
Adding piperine raised resveratrol exposure (AUC) to 229% of resveratrol alone, and peak concentration to 1,544%. Glucuronide metabolite exposure fell by roughly 80%, which is consistent with blocked glucuronidation.
Source: Johnson et al., Molecular Nutrition & Food Research, 2011 (C57BL mice, oral gavage).
Those are large effects and the mechanism fits. The doses do not carry across neatly. The standard body-surface-area sum divides a mouse dose by 12.3 to get a human one.
Run that arithmetic and the mice received the rough equivalent of 570 mg of resveratrol and 57 mg of piperine for a 70 kg adult. Typical capsules carry 5 to 10 mg of BioPerine.
So the headline figure comes from mice given about six times the piperine most people take. Mice, so far.
The only human trial that tested the pair
Northumbria University ran the test in 2014. Twenty-three adults, randomised, double-blind, crossover. Each took a dummy pill, 250 mg trans-resveratrol, or 250 mg trans-resveratrol with 20 mg piperine, on days a week apart.
The team tracked blood flow in the frontal cortex with near-infrared light while people worked through mental tasks. With piperine, blood flow during those tasks rose against both the dummy pill and resveratrol alone.
Cognitive performance did not change. Mood did not change. Blood pressure did not change.
Key Study: More Blood Flow, Same Blood Levels
In 23 adults, 250 mg trans-resveratrol with 20 mg piperine increased frontal cortex blood flow during cognitive tasks compared with resveratrol alone. Plasma concentrations of resveratrol and its metabolites were not significantly different between treatments. The authors concluded that piperine altered bioefficacy without altering bioavailability.
Source: Wightman et al., British Journal of Nutrition, 2014 (n=23 crossover; pharmacokinetic cohort n=6).
Read that last line again. In the one human trial that measured it, piperine did not raise plasma resveratrol.
It is one trial, in 23 people, on a stand-in marker, with twice the piperine of a typical capsule. It is also all the direct human evidence there is.
The curcumin number does not transfer
Almost every bioenhancer claim traces back to one 1998 paper in Planta Medica. Ten healthy volunteers took 2 g of curcumin with or without 20 mg of piperine. Bioavailability rose by 2,000%.
That figure launched an entire category. It is also about a different molecule.
Curcumin starts from close to zero in the blood, so a huge multiple is easy to hit. It dissolves differently, clears differently, and is tagged by a different mix of enzymes. No one else has since matched that 2,000% figure.
Borrowing a curcumin multiple and printing it beside a stilbene is marketing, not pharmacology.
What actually raises plasma resveratrol
Particle size has done better than pepper. In a Leicester trial, nine patients took 5 g daily of SRT501, a micronised resveratrol formulation, for 14 days. Mean plasma resveratrol after a single dose was 1,942 ng/mL — about 3.6 times published values for the same dose of ordinary resveratrol.
Grinding the powder finer beats the enzymes on speed. More of the dose crosses the gut wall before the tagging catches up. It is dull, and it works.
Raising the dose also works, with falling returns.
Neither route is open to a UK supplement at gram doses anyway. Which brings us to the practical part.
What to do with this
GB law allows trans-resveratrol in capsules and tablets at up to 150 mg a day for adults. Labels must also carry a line for anyone on medication. That ceiling sits well below every blood-level study quoted here. We covered how the approval works in our piece on the GB novel foods process.
At 150 mg the honest summary of the outcome data is modest. Pooled across six randomised trials in 247 people, resveratrol produced no overall change in blood pressure; only the subgroup taking 150 mg or more showed a systolic fall, and that estimate ran from 2.8 to 21.0 mmHg.
So judge a resveratrol product on three things. The isomer, which we unpacked in trans versus cis resveratrol. The assayed amount in the capsule. And whether the company will tell you where the evidence stops.
Piperine belongs in the third bucket. Our own NMN + Resveratrol carries 10 mg of BioPerine. The mechanism is well mapped, the ingredient is cheap, and people have eaten pepper for a very long time. On the human data, though, it is a good theory rather than a measured rise in blood levels. We would rather say that than imply more.
If you take digoxin, ciclosporin, a statin, or anything else cleared by CYP3A4, raise the pepper extract with your pharmacist before you start. It is a five-minute conversation.
And if a brand quotes 2,000% on a resveratrol label, you now know which molecule that number belongs to. It is not this one. For how resveratrol pairs with NAD+ precursors, see NMN and resveratrol together.
References
- Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E., Walle, U.K. (2004). "High absorption but very low bioavailability of oral resveratrol in humans." Drug Metabolism and Disposition, 32(12), 1377-1382. PMID: 15333514.
- Boocock, D.J., Faust, G.E.S., Patel, K.R., et al. (2007). "Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent." Cancer Epidemiology, Biomarkers & Prevention, 16(6), 1246-1252. DOI: 10.1158/1055-9965.EPI-07-0022.
- Johnson, J.J., Nihal, M., Siddiqui, I.A., et al. (2011). "Enhancing the bioavailability of resveratrol by combining it with piperine." Molecular Nutrition & Food Research, 55(8), 1169-1176. PMID: 21714124.
- Wightman, E.L., Reay, J.L., Haskell, C.F., Williamson, G., Dew, T.P., Kennedy, D.O. (2014). "Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation." British Journal of Nutrition, 112(2), 203-213.
- Bhardwaj, R.K., Glaeser, H., Becquemont, L., Klotz, U., Gupta, S.K., Fromm, M.F. (2002). "Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4." Journal of Pharmacology and Experimental Therapeutics, 302(2), 645-650. PMID: 12130727.
- Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., Srinivas, P.S. (1998). "Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers." Planta Medica, 64(4), 353-356. PMID: 9619120.
- Howells, L.M., Berry, D.P., Elliott, P.J., et al. (2011). "Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases." Cancer Prevention Research, 4(9), 1419-1425. PMID: 21680702.
- Liu, Y., Ma, W., Zhang, P., He, S., Huang, D. (2015). "Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials." Clinical Nutrition, 34(1), 27-34. DOI: 10.1016/j.clnu.2014.03.009.
Continue Reading
April 4, 2026